KPMG has selected a highly topical subject and tackles the issue head on with a pragmatic ‘how to’ approach. The firm succeeds in conveying a realistic sense of urgency, challenging those who are assuming that the impact of biosimilars on the US market will be very gradual.
This report seamlessly incorporates qualitative data from academic experts and secondary research; profiling the authors, with details of their relevant experience, further boosts reader confidence and trust. The written style is simple and engaging – quite a feat when dealing with a technically complex issue – and examples from industry are used very effectively throughout.
Quality score
Differentiation
| Appeal
| Resilience
| Prompting action
| Total
|
